eagle-i University of Hawaii at ManoaUniversity of Hawaii at Manoa
See it in Search
This page is a preview of the following resource. Continue onto eagle-i search using the button on the right to see the full record.

ASSURE: adjuvant sorafenib or sunitinib for ufavorable renal carcinoma

eagle-i ID


Resource Type

  1. Clinical trial


  1. ClinicalTrials.gov url
  2. Intervention
  3. Intervention
  4. Intervention
  5. Intervention
  6. Intervention
    Adjuvant therapy
  7. Resource Description
    Surgery is the primary treatment for most cases of kidney cancer. While surgery alone often cures patients with early stage disease, individuals with more advanced disease have an increased risk of cancer recurrence after surgery. In this trial, patients who have tumors that can be surgically removed and who are at high risk for recurrence are given sunitinib (Sutent®), sorafenib (Nexavar®), or a placebo as postoperative (adjuvant) therapy. Patients given the placebo will be receiving the current standard of care for their condition, which is no adjuvant therapy. Sunitinib and sorafenib are targeted therapies that block cell proliferation and the growth of new blood vessels to tumors (a process called angiogenesis). Angiogenesis is important for the growth and spread of malignant kidney tumors and blocking it may help prevent the growth of cancer cells that remain after surgery.
  8. Contact
    Berenberg, Jeffrey
  9. PI
    Berenberg, Jeffrey
  10. Topic
    kidney cancer
  11. Study Population
    Males and females age 18 and older with histologically or cytologically confirmed renal cell carcinoma, including clear cell carcinoma and nonclear cell carcinoma; no collecting duct or medullary carcinomas.
  12. Website(s)
  13. Website(s)
  14. Funded by
    Cancer Trials Support Unit
  15. Phase
    Phase 3 clinical trial
  16. Performed by
    Clinical Protocol & Data Management Shared Resource
Provenance Metadata About This Resource Record
Copyright © 2016 by the President and Fellows of Harvard College
The eagle-i Consortium is supported by NIH Grant #5U24RR029825-02 / Copyright 2016